Fair ValueUpdated November 18, 2026

BDX Dividend Analysis — Is Becton, Dickinson and Company Undervalued in 2026?

Current Yield

1.84%

Quality Score

65/100

Price

$215.49

5Y Div. CAGR

6.0%

Research view

BDX is balanced, but not a bargain

Becton, Dickinson and Company is near fair value with a 1.84% yield versus a 1.71% historical median. Existing holders can focus on dividend safety and growth; new buyers may want either a better yield or stronger evidence that the dividend growth rate can compound through the next cycle.

Entry signal

Fair Value

Dividend quality

Good

Dividend record

54 years

Healthcare dividend deep dive

How to read the BDX dividend setup

Becton Dickinson is not a yield-chasing healthcare story. The dividend case rests on recurring medical demand, a long growth record, and whether the current yield is unusually attractive for a device and diagnostics business that investors often value for durability.

That is where a dividend-history lens helps. BDX can look less exciting than a high-yield pharma stock on current income alone, so the research question is whether valuation, payout coverage, and dividend growth make the lower starting yield worth the quality trade-off.

Research questions

  • Is BDX cheap relative to its own dividend yield history?
  • Does payout safety compensate for a lower starting yield?
  • How does BDX compare with healthcare dividend peers on quality and growth?

Go deeper

Why BDX Matters Now

Becton, Dickinson and Company is trading at a fair valuation relative to its dividend history. Current yield 1.8% vs historical max 2.6% (71% of maximum). 14 consecutive years without a dividend cut. Reasonable payout ratio of 72%.

Weiss Valuation: Where Does BDX Stand Today?

At 1.84%, BDX's current yield sits near the midpoint of its 10-year historical range (1.37%–2.59%), with a historical median of 1.71%. The Weiss model rates this as fair value — neither a compelling entry nor a reason to sell an existing position.

The undervalued price threshold — the level at which BDX historically becomes an attractive buy — currently sits at $184.71. The overvalued threshold, above which the stock is historically expensive, is $295.36. The current price of $215.49 places the stock between the two bands, in the fair value zone.

Dividend Quality Assessment

Becton, Dickinson and Company scores 65/100 on DividendVisual's quality scale — a Good rating, indicating a well-covered, growing dividend with manageable risk. Key metrics: a 72% payout ratio, the dividend consumes 28% of free cash flow, growing at 6.0% annually over the past 5 years.

Becton, Dickinson and Company has raised its dividend for 54 consecutive years — qualifying it as a Dividend King, the most elite category of income stocks.

The current payout ratio is 72% — a moderate level. The dividend is well-covered but investors should monitor any trend toward higher payout.

Peer Context: Is BDX the Best Setup?

BDX is not the only candidate in Healthcare. CVS offers a higher current yield, while CVS screens higher on quality. That makes peer comparison important before treating BDX's Weiss signal as the best available setup.

10-Year Yield History

Over the past decade, Becton, Dickinson and Company's dividend yield has ranged from a low of 1.37% (when the stock was most expensive relative to its dividend) to a high of 2.59% (when it was most attractively priced). The historical median yield — a reasonable proxy for fair value — is 1.71%.

Investors who consistently bought BDX near its historical yield maximum and held for 3–5 years have, historically, earned both above-average income and above-average capital appreciation as the yield mean-reverted toward the median. This is the core logic of yield-based valuation: price and yield are inversely related, so buying high yield means buying low price.

Income Projection: What BDX Could Generate

A $10,000 investment at the current price and yield would generate approximately $184 in year-one income. With dividends reinvested and a 6.0% annual growth rate maintained, that same investment would produce roughly $424 per year in income by year 10 — a yield on cost of 4.2%.

These projections assume no share price appreciation — only the compounding effect of reinvested dividends at a constant price. In practice, share price changes will affect the total return. The projection is intended to illustrate the power of dividend reinvestment over time, not to predict a specific outcome.

Key Risks to Consider

Becton, Dickinson and Company's dividend appears well-supported by current earnings and cash flow. No material red flags are flagged by the quality model, though macro risks (rising rates, sector disruption) always apply.

For healthcare dividend stocks, patent cycles, reimbursement pressure, product pipelines, and litigation can matter as much as current payout ratios. A safe-looking dividend still needs durable earnings power behind it.

Beyond company-specific factors, all dividend stocks carry interest rate risk: when rates rise, income investors have alternatives, and dividend stock valuations tend to compress. Becton, Dickinson and Company's position in the Healthcare sectorshould be evaluated in the context of your portfolio's overall rate sensitivity.

What to Watch Next

  • Yield moving toward 2.59% would strengthen the undervaluation signal; yield falling toward 1.71% would indicate mean reversion.
  • Payout ratio staying below 72% would support dividend flexibility.
  • Free-cash-flow payout near 28% should be monitored for deterioration.
  • Dividend growth above 6.0% would confirm the income-compounding case; a slowdown would reduce the appeal.
  • Any break in the 54-year dividend growth streak would materially change the thesis.

Bottom Line

Becton, Dickinson and Company is trading at fair value by the Weiss method — neither a bargain nor overpriced. Income investors already holding the stock can continue to do so comfortably. Those looking to initiate a position might consider waiting for a dip toward the undervalued band, or beginning a partial position now and adding on weakness.

Compare BDX with other dividend stocks

Use the screener to compare yield, quality score, Weiss signal, payout coverage, and dividend growth across the full universe.